rheumatoid arthritis

February 20, 2017February 20, 2017

Vaccine Against Pneumococcal Pneumonia May Not Prevent Infection in RA Patients

Vaccination against pneumococcal pneumonia may not protect patients with rheumatoid arthritis (RA) at risk of infection from pneumonia, according to the results of a clinical trial in Japan. The study ... Read more

February 17, 2017February 17, 2017

RA Patients Treated with Olumiant Show Improvements Compared to Humira, Placebo

News, rheumatoid arthritis

In a pivotal Phase 3 clinical trial, Olumiant (baricitinib) improved patients’ outcomes in the treatment of moderate-to-severe rheumatoid arthritis (RA), in comparison to Humira (adalimumab) and placebo, according to a ... Read more

February 15, 2017February 15, 2017

European Commission OKs Marketing Olumiant Tablets for Adults with Active RA

News, rheumatoid arthritis

The European Commission has granted marketing authorization for Olumiant (baricitinib) 4 mg and 2 mg tablets for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have ... Read more

February 6, 2017February 6, 2017

Newly Identified T-cell in RA Patients May Leapfrog Autoimmune Treatment Development

News, rheumatoid arthritis

An entirely new type of T-cell found in people with rheumatoid arthritis works in a unique way to drive disease processes in the joints by teaming up with other immune ... Read more

February 1, 2017February 1, 2017

EU Closer to Approving ABP 501 as Alternative to Humira for Rheumatoid Arthritis

News, rheumatoid arthritis

Amgen has taken a key step toward obtaining European Union approval of its ABP 501 biosimilar therapy for rheumatoid arthritis (RA) and other conditions. The European Medicines Agency’s Committee for Medicinal Products for Human ... Read more

January 30, 2017January 30, 2017

NIH Awards $1.8M to Study of Enzyme’s Role in Potential Therapies for RA and Other Diseases

News, rheumatoid arthritis

A nearly $1.8 million grant given a research team at The Scripps Research Institute (TSRI) in Florida will be used to study an enzyme that controls cell survival and death, with the goal ... Read more

January 20, 2017January 20, 2017

14.4M Euros Awarded to European Consortium to Develop Therapies for Inflammatory Diseases

News, rheumatoid arthritis

Based on the prevalence of chronic inflammatory diseases worldwide, an affiliation of nine European countries, including academic and industry partners, has been awarded 14.4 million euros (around $15.3 million U.S.) to ... Read more

January 18, 2017January 18, 2017

Review Period for Eli Lilly’s RA Therapy Baricitinib Extended by FDA

News, rheumatoid arthritis

The U.S. Food and Drug Administration (FDA) has extended the review period for a new drug application (NDA) for Eli Lilly’s investigational treatment baricitinib for rheumatoid arthritis (RA). The announcement was ... Read more

January 11, 2017January 11, 2017

Phase 2 Study in Brazil to Test Efficacy of IL-6 Antibody, Possible Low-Cost Therapy Option

News, rheumatoid arthritis

Brazilian regulatory authorities have approved a Phase 2 clinical trial to evaluate gerilimzumab, a new antibody against the IL-6 cytokine, as a treatment for rheumatoid arthritis (RA). The protocol was developed specifically for patients ... Read more

January 6, 2017January 6, 2017

Baricitinib Closer to Obtaining European Approval for Treatment of Rheumatoid Arthritis

News, rheumatoid arthritis

European regulators have taken a key step toward approving baricitinib to treat those with moderate to severe rheumatoid arthritis (RA). The European Medicines Agency’s Committee for Medicinal Products for Human Use ... Read more